Status:
UNKNOWN
Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study
Lead Sponsor:
Konkuk University Medical Center
Collaborating Sponsors:
Roche Diagnostics GmbH
Foundation Medicine
Conditions:
Adenocarcinoma of Lung
EGFR Activating Mutation
Eligibility:
All Genders
19+ years
Brief Summary
The concomitant co-mutation with epidermal growth factor receptor (EGFR) mutation might influence the clinical outcomes. The investigators will identify the impact of concommitant mutation on clinical...
Detailed Description
The current standard therapies in the treatment of advanced EGFR-mutated lung cancer patients are the 1st or 2nd EGFR-TKIs. Although 70-80% of patients treated by EGFR-TKIS show good responses, they h...
Eligibility Criteria
Inclusion
- Signed Informed Consent Form
- Age ≥19 years
- EGFR-mutated stage IV lung adenocarcinoma patients
- Archival biopsy tissues which are from core needle biopsies, endobronchial ultrasound (EBUS) guided- lymph node biopsy or lymph node excisional biopsy at baseline and at radiologic progression
- Availability of the 10 unstained slides and 1 H\&E slides at pre/ post TKI treatment
- Samples should contain a minimum of 20% viable tumor cells that preserve
Exclusion
- Tumor tissue from bone metastases that have been decalcified are not acceptable.
- \-
Key Trial Info
Start Date :
September 30 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04122833
Start Date
September 30 2019
End Date
December 31 2024
Last Update
August 18 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Asan medical center
Seoul, South Korea, 05505
2
Catholic university medical center, Seoul St. Mary's Hospital
Seoul, South Korea